Merck Animal Health Receives Positive Opinion from EU CVMP for Numelvi Tablets for Dogs
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., has announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for Numelvi (atinvicitinib) tablets for dogs. This marks an important step toward the availability of Numelvi in the European Union.
Merck Animal Health Thrives in 2024: Steady Growth Driven by Pricing, Demand, and Innovation
Merck Animal Health has once again demonstrated its resilience and leadership in the veterinary industry, closing 2024 with an impressive $5.9 billion in sales, marking a 4% increase from the previous year. Despite challenges posed by foreign exchange fluctuations, the company's strategic pricing, strong product demand, and key acquisitions helped drive steady growth.
Merck Animal Health's Groundbreaking Initiative Boosts Minority-Owned Cattle Farms – Here’s How It’s Transforming the Industry
Merck Animal Health, in partnership with the Winston County Self Help Cooperative, has launched the Beef Cattle Herd Health Initiative in East Central Mississippi. This two-year program aims to improve the economic and environmental sustainability of minority-owned cattle herds through education, training, and hands-on support. Learn more about this transformative initiative.
Revolutionizing Dairy Farming: Merck Animal Health’s New Technology Tracks Calf Health Like Never Before!
Discover how Merck Animal Health's SENSEHUB Dairy Youngstock is transforming dairy farming with the first-ever monitoring technology for calves. This groundbreaking tool from birth to 12 months helps dairy producers enhance calf care, improve herd health, and boost overall productivity by using data-driven insights to identify and treat health issues early.
Game Changer Alert: Merck Animal Health Unveils Revolutionary Vaccine for Swine Health
Prepare for a swine health revolution! Merck Animal Health has just unveiled a groundbreaking vaccine that's set to transform the industry. Say hello to Sequivity with Microsol Diluvac Forte (MDF) adjuvant, the latest weapon in the fight against swine diseases.
This cutting-edge vaccine harnesses the power of RNA Particle Technology, a game-changing innovation that promises safe, flexible, and precise protection for gilts and sows. By combining the trusted MDF adjuvant with the Sequivity platform, Merck has created a dynamic duo capable of addressing the unique needs of specific herds.
Merck Animal Health’s $1.3B Aqua Business Acquisition
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions.